10-43126647-A-G
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS1
The NM_020975.6(RET):āc.3112A>Gā(p.Thr1038Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000564 in 1,613,988 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_020975.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RET | NM_020975.6 | c.3112A>G | p.Thr1038Ala | missense_variant | Exon 19 of 20 | ENST00000355710.8 | NP_066124.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000454 AC: 69AN: 152004Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000600 AC: 151AN: 251466Hom.: 0 AF XY: 0.000589 AC XY: 80AN XY: 135906
GnomAD4 exome AF: 0.000576 AC: 842AN: 1461866Hom.: 0 Cov.: 31 AF XY: 0.000576 AC XY: 419AN XY: 727228
GnomAD4 genome AF: 0.000454 AC: 69AN: 152122Hom.: 0 Cov.: 32 AF XY: 0.000471 AC XY: 35AN XY: 74364
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:4
- -
- -
- -
- -
This variant is associated with the following publications: (PMID: 24336963, 28873162, 24429398) -
not specified Uncertain:1Benign:3
- -
Variant summary: RET c.3112A>G (p.Thr1038Ala) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0006 in 251466 control chromosomes, predominantly within the Finnish- and Non-Finnish European subpopulations, at a frequency of about 0.0019 and 0.001, respectively (gnomAD). The observed variant frequencies in these subpopulations are approximately 25-50 fold higher than the estimated maximal expected allele frequency (MPAF) for a pathogenic variant in RET causing Multiple Endocrine Neoplasia Type 2 phenotype (3.7e-05), suggesting that the variant is a benign polymorphism. The variant, c.3112A>G, has been reported in the literature in multigene panel testing studies in individuals affected with various tumor phenotypes, mostly outside the RET gene associated tumor spectrum, and without strong evidence for causality (e.g. Zhang_2015, Kim_2018, Zhunussova_2019, Henn_2019, Backman_2020). These report(s) do not provide unequivocal conclusions about association of the variant with Multiple Endocrine Neoplasia Type 2. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seventeen submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments, classifying the variant as likely benign (n=12), VUS (n=4), or benign (n=1). Based on the evidence outlined above, the variant was classified as likely benign. -
- -
The frequency of this variant in the general population (http://gnomad.broadinstitute.org) is higher than would generally be expected for pathogenic variants in this gene. -
Multiple endocrine neoplasia, type 2 Benign:3
- -
- -
- -
Multiple endocrine neoplasia type 2A Benign:2
- -
- -
Hereditary cancer-predisposing syndrome Benign:2
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
Ewing sarcoma of soft tissue Uncertain:1
- -
Pheochromocytoma Benign:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. -
Renal hypodysplasia/aplasia 1 Benign:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases was too high to be consistent with this variant causing disease. Therefore, this variant is classified as benign. -
Hirschsprung disease, susceptibility to, 1 Benign:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases was too high to be consistent with this variant causing disease. Therefore, this variant is classified as benign. -
Multiple endocrine neoplasia Benign:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases was too high to be consistent with this variant causing disease. Therefore, this variant is classified as benign. -
RET-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at